StockData
Scribe Therapeutics, Inc. logo

Scribe Therapeutics, Inc. (SCTX) stock

SCTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026
$14.05−1.72 (-10.91%)

Close on Nov 18, 2026Market cap $34.92MP/E –Yield –

Scribe Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

No free cash flow figures for Scribe Therapeutics

Scribe Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Scribe Therapeutics figures

See a number that looks wrong?